High‐dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

Overview of attention for article published in Hepatology, May 2009

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

blogs: 1 blog
twitter: 6 X users
patent: 5 patents

wikipedia: 4 Wikipedia pages
reddit: 2 Redditors
guideline: 12 clinical guideline sources

Readers on

mendeley: 246 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 15,032 followers.

RT @Gastronaut___: @Radion_Popalzai standard dose UDCA may be given. ( AASLD permits it). EASL doesn’t recommend routine use. https://t.c…

@Radion_Popalzai standard dose UDCA may be given. ( AASLD permits it). EASL doesn’t recommend routine use. https://t.co/Qt2yvI3RZc

Ursodeoxy acid assoc with improved LFTs in sclerosing cholangitis but associated with higher adverse events. http://t.co/U5IkD5YRL7 #BSPGHAN

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 2 additional X posts.